Zobrazeno 1 - 10
of 398
pro vyhledávání: '"circulating tumor cell—CTC"'
Publikováno v:
Sensors and Actuators Reports, Vol 6, Iss , Pp 100169- (2023)
Combining bioaffinity-based techniques with microfluidics is an effective strategy for the selective isolation of rare circulating tumor cells (CTCs) among peripheral blood cells. In this scope, designing a microfluidic channel with high cell-surface
Externí odkaz:
https://doaj.org/article/3e2dfdfc93484bb393584d77e09db5d4
Autor:
Walla Malkawi, Areeb Lutfi, Maaz Khan Afghan, Lamisha Mashiyat Shah, Lillian Costandy, Arturo B. Ramirez, Thaddeus C. George, Fatima Toor, Aliasger K. Salem, Pashtoon Murtaza Kasi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveMost of the work in terms of liquid biopsies in patients with solid tumors is focused on circulating tumor DNA (ctDNA). Our aim was to evaluate the feasibility of using circulating tumor cells (CTCs) in peripheral blood samples from patients
Externí odkaz:
https://doaj.org/article/0006f2adcd64453e825779bc4990c68c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Gianna Di Sario, Valeria Rossella, Elvira Smeralda Famulari, Aurora Maurizio, Dejan Lazarevic, Francesca Giannese, Claudia Felici
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
In the last years, liquid biopsy gained increasing clinical relevance for detecting and monitoring several cancer types, being minimally invasive, highly informative and replicable over time. This revolutionary approach can be complementary and may,
Externí odkaz:
https://doaj.org/article/4341f2e21a8c429ab4ce49492478cdff
Autor:
Begum Sen-Dogan, Mehmet Alper Demir, Buket Sahin, Ender Yildirim, Gizem Karayalcin, Sebnem Sahin, Ege Mutlu, Taylan Berkin Toral, Ebru Ozgur, Ozge Zorlu, Haluk Kulah
Publikováno v:
Biosensors, Vol 13, Iss 10, p 938 (2023)
The isolation of circulating tumor cells (CTCs) from peripheral blood with high efficiency remains a challenge hindering the utilization of CTC enrichment methods in clinical practice. Here, we propose a microfluidic channel design for the size-based
Externí odkaz:
https://doaj.org/article/bc8d76d401f4403eab78549804c64b06
Autor:
Anobel Tamrazi, Srividya Sundaresan, Aishwarya Gulati, Frederick J. Tan, Vibhor Wadhwa, Bjarne R. Bartlett, Luis A. Jr. Diaz
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionCirculating tumor-derived biomarkers can potentially impact cancer management throughout the continuum of care. This small exploratory study aimed to assess the relative levels of such biomarkers in the tumor-draining vascular beds in pat
Externí odkaz:
https://doaj.org/article/d59ad7738e504796842c253f6476a823
Publikováno v:
Nanoscale Research Letters, Vol 16, Iss 1, Pp 1-6 (2021)
Abstract It is significant to develop an efficient early detection and prediction method for ovarian cancer via a facile and low-cost approach. To address such issues, herein, we develop a novel circulating tumor cell (CTC) detection method to sensit
Externí odkaz:
https://doaj.org/article/2a31471b59cb4a8bab1d06460568f155
Publikováno v:
Journal of Cardiothoracic Surgery, Vol 16, Iss 1, Pp 1-11 (2021)
Abstract Background The optimal sequence of pulmonary vessel interruption during lung cancer resection remains controversial. This review aimed to elucidate the association of vein-first versus artery-first ligation and survival of the patients. Meth
Externí odkaz:
https://doaj.org/article/721a930c5ce740e495542ac0552b109c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Long Dao, Dristhi Ragoonanan, Izhar Batth, Arun Satelli, Jessica Foglesong, Jian Wang, Wafik Zaky, Jonathan B. Gill, Diane Liu, Aisha Albert, Nancy Gordon, Winston Huh, Douglas Harrison, Cynthia Herzog, Eugenie Kleinerman, Richard Gorlick, Najat Daw, Shulin Li
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundDespite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as < 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such,
Externí odkaz:
https://doaj.org/article/ecabc7e1fe53496c97da19405d1ff875